{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:11:04Z","timestamp":1778512264540,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Duke Translational Medicine Institute\/Duke"},{"name":"Clinical and Translational Science Award (CTSA)","award":["UL1TR001117"],"award-info":[{"award-number":["UL1TR001117"]}]},{"name":"Alice and Y.-T. Chen Pediatric Genetics and Genomics Center"},{"name":"National Mucopolysaccharidoses (MPS) Society"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AR065873"],"award-info":[{"award-number":["R01AR065873"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["GM086524"],"award-info":[{"award-number":["GM086524"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ymgme.2015.09.012","type":"journal-article","created":{"date-parts":[[2015,10,10]],"date-time":"2015-10-10T18:24:56Z","timestamp":1444501496000},"page":"114-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease"],"prefix":"10.1016","volume":"117","author":[{"given":"Sang-oh","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rand","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Steet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ymgme.2015.09.012_bb0005","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.012_bb0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","article-title":"Enzyme replacement and enhancement therapies for lysosomal diseases","volume":"27","author":"Desnick","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.012_bb0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2015.09.012_bb0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2015.09.012_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.012_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"Beta2 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.09.012_bb0035","doi-asserted-by":"crossref","DOI":"10.1096\/fj.13-244202","article-title":"Adjunctive beta2-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease","author":"Farah","year":"2014","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.012_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","article-title":"Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.ymgme.2015.09.012_bb0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1358\/dot.2012.48.5.1782932","article-title":"Current status of beta-blockers for the treatment of hypertension: an update","volume":"48","author":"Chrysant","year":"2012","journal-title":"Drugs Today"},{"issue":"5","key":"10.1016\/j.ymgme.2015.09.012_bb0050","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.ymgme.2015.09.012_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genitourin. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.012_bb0060","first-page":"88","article-title":"The C57BL\/6 genetic background confers cardioprotection in iron-overloaded mice","volume":"11","author":"Musumeci","year":"2013","journal-title":"Blood Transfus."},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.012_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.012_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ymgme.2015.09.012_bb0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.gim.0000195896.04069.5f","article-title":"Electrocardiographic response to enzyme replacement therapy for Pompe disease","volume":"8","author":"Ansong","year":"2006","journal-title":"Genitourin. Med."},{"issue":"22","key":"10.1016\/j.ymgme.2015.09.012_bb0080","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.102.22.2751","article-title":"Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy","volume":"102","author":"Manning","year":"2000","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ymgme.2015.09.012_bb0085","doi-asserted-by":"crossref","first-page":"H1521","DOI":"10.1152\/ajpheart.00491.2014","article-title":"Disruption of type 5 adenylyl cyclase prevents beta-adrenergic receptor cardiomyopathy: a novel approach to beta-adrenergic receptor blockade","volume":"307","author":"Yan","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"8","key":"10.1016\/j.ymgme.2015.09.012_bb0090","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0006-2952(86)90283-2","article-title":"Selective lysosomal uptake and accumulation of the beta-adrenergic antagonist propranolol in cultured and isolated cell systems","volume":"35","author":"Cramb","year":"1986","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.ymgme.2015.09.012_bb0095","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.4155\/bio.09.128","article-title":"Mechanisms of amine accumulation in, and egress from, lysosomes","volume":"1","author":"Goldman","year":"2009","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.012_bb0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.012_bb0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.resp.2013.03.004","article-title":"Postural effects on lung and chest wall volumes in late onset type II glycogenosis patients","volume":"186","author":"Remiche","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"issue":"5","key":"10.1016\/j.ymgme.2015.09.012_bb0110","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1152\/jappl.1989.66.5.2196","article-title":"Effects of undernutrition on diaphragm fiber size, SDH activity, and fatigue resistance","volume":"66","author":"Sieck","year":"1989","journal-title":"J. Appl. Physiol."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.012_bb0115","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ymgme.2013.06.023","article-title":"Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function","volume":"110","author":"Gaeta","year":"2013","journal-title":"MolGenet Metab"},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.012_bb0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid {alpha}-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ymgme.2015.09.012_bb0125","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nm0604-584","article-title":"Balancing muscle hypertrophy and atrophy","volume":"10","author":"Hoffman","year":"2004","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2015.09.012_bb0130","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.humpath.2011.09.020","article-title":"Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study","volume":"43","author":"Chimenti","year":"2012","journal-title":"Hum. Pathol."},{"issue":"11","key":"10.1016\/j.ymgme.2015.09.012_bb0135","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ncb1101-1014","article-title":"Akt\/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo","volume":"3","author":"Bodine","year":"2001","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.012_bb0140","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.012_bb0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2012.09.010","article-title":"Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease","volume":"107","author":"Nilsson","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2015.09.012_bb0150","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/jps.24087","article-title":"Time-dependent effects of hydrophobic amine-containing drugs on lysosome structure and biogenesis in cultured human fibroblasts","volume":"103","author":"Logan","year":"2014","journal-title":"J. Pharm. Sci."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T11:12:00Z","timestamp":1567249920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719215300585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1096719215300585"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.09.012","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}